This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA. If you would like continuing education credit for the webinar, click on the links in the table below to access the webinar + CME/CMLE or webinar + SAM


Speaker:

      Ahmet Zehir, PhD     

Moderator:

Jonathan Nowak, MD, PhD

Description: As tumor mutational burden (TMB) is gaining traction as a predictive biomarker for immunotherapy, the challenge of reporting TMB back to the treating oncologists and patients in an informative way still exists. In this webinar, we will discuss strategies of implementing TMB in the clinical laboratory, how different TMB values reported from various assays compare to each other, and how to communicate the results in a clear way.

Duration: 1 hr

Level of Instruction: Basic

This webinar is part 3 of a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here.

This program has been supported through an educational grant from Bristol-Myers Squibb.


Click on the links below to purchase continuing education credit.

Credit Type Number of Credit Hours Click on link to purchase:
CME/CMLE 1.0

Purchase Webinar + CME/CMLE

(Free for all)

SAM 1.0

Purchase Webinar + SAM

(Free for all)

Continuing Education Credit must be purchased and claimed by December 31, 2020

You may also be interested in:

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
September 26, 2018
Course Objectives
  • Describe challenges and opportunities in the implementation of TMB testing in the clinical laboratory.
  • Discuss the various ways by which TMB can be reported back to the clinicians and patients.
Pre-Test
Tumor Mutational Burden: Result Reporting and Application to Improve Patient Care
Post-Test
QA Session
Individual topic purchase: Selected
Products
Zehir Presentation
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00